Jorge DiMartino
Chief Medical Officer & Executive Vice President - Clinical & Translational Development Plexium Inc.
Seminars
Wednesday 24th September 2025
Developing a Companion Diagnostic for a SMARCA2 Direct Degrader in Cancer
11:50 am
- SMARCA4 mutations are a heterogeneous group of genomic abnormalities in cancer, some of which create a dependency on its paralog, SMARCA2
- Prospective identification of patients who would benefit from treatment with a selective SMARCA2 degrader will require a comprehensive analysis of data from ongoing clinical studies and pre-clinical models
